How is abatacept administered in patients with rheumatoid arthritis (RA)?

Updated: Feb 07, 2020
  • Author: Howard R Smith, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Maintenance doses of abatacept may be administered as a monthly intravenous (IV) infusion or by the patient as a weekly SC injection. [96] In patients with RA who have previously had treatment failure with anti-TNF therapy, abatacept has been shown to demonstrate consistent safety and efficacy that are maintained from 6 months to 5 years of therapy. [97]

A head-to-head phase IIIb randomized noninferiority trial found that subcutaneous (SC) abatacept and SC adalimumab were equally effective in RA patients, with comparable safety (though adalimumab was associated with more injection-site reactions). [98] Adding either treatment to background methotrexate produced similar American College of Rheumatology 20% improvement response (ACR20) rates and similar rates of radiographic nonprogression. In view of these findings, clinicians may reasonably conclude that the 2 agents are substantially equivalent for treating RA.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!